Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Mostrar más
Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and...
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.08 | 1.39130434783 | 5.75 | 6 | 5.22 | 1022363 | 5.54724767 | CS |
| 4 | -1.0585 | -15.3661900269 | 6.8885 | 7.58 | 5.22 | 1092533 | 6.16163115 | CS |
| 12 | -2.83 | -32.6789838337 | 8.66 | 9.29 | 5.22 | 874908 | 7.37964281 | CS |
| 26 | -14.96 | -71.9576719577 | 20.79 | 28.38 | 5.22 | 927206 | 11.96736663 | CS |
| 52 | -15.72 | -72.9466357309 | 21.55 | 36.25 | 5.22 | 898210 | 19.26531029 | CS |
| 156 | -16.33 | -73.6913357401 | 22.16 | 36.25 | 5.22 | 543881 | 17.66188515 | CS |
| 260 | -34.17 | -85.425 | 40 | 55.11 | 5.22 | 452429 | 19.18169558 | CS |
Monksdream
2 semanas hace
Monksdream
2 meses hace
Monksdream
2 meses hace
Biggeoff
11 meses hace
Monksdream
11 meses hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
